Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 131, Issue 7
February 15 2018
Issue Cover

Table of Contents

BLOOD COMMENTARIES

Lymphoid Neoplasia
Distinct miRNA profile in prognosis of early CTCL
Mariusz A. Wasik
View Articletitled, Distinct miRNA profile in prognosis of early CTCL
Lymphoid Neoplasia
BRD4: epigenetic origin and target of CTCL
Xiaohong Zhao,Jianguo Tao
View Articletitled, BRD4: epigenetic origin and target of CTCL
PLATELETS AND THROMBOPOIESIS
Only the strong: when antibodies hold on
Wendy E. Thomas
View Articletitled, Only the strong: when antibodies hold on
THROMBOSIS AND HEMOSTASIS
Clot structure predicts recurrent thrombosis
Nathan J. White
View Articletitled, Clot structure predicts recurrent thrombosis

PLENARY PAPER

Red Cells, Iron, and Erythropoiesis
A landscape of germ line mutations in a cohort of inherited bone marrow failure patients
CME Clinical Trials & Observations
Olivier Bluteau,Marie Sebert,Thierry Leblanc,Régis Peffault de Latour,Samuel Quentin,Elodie Lainey,Lucie Hernandez,Jean-Hugues Dalle,Flore Sicre de Fontbrune,Etienne Lengline,Raphael Itzykson,Emmanuelle Clappier,Nicolas Boissel,Nadia Vasquez,Mélanie Da Costa,Julien Masliah-Planchon,Wendy Cuccuini,Anna Raimbault,Louis De Jaegere,Lionel Adès,Pierre Fenaux,Sébastien Maury,Claudine Schmitt,Marc Muller,Carine Domenech,Nicolas Blin,Bénédicte Bruno,Isabelle Pellier,Mathilde Hunault,Stéphane Blanche,Arnaud Petit,Guy Leverger,Gérard Michel,Yves Bertrand,André Baruchel,Gérard Socié,Jean Soulier
View Articletitled, A landscape of germ line mutations in a cohort of inherited bone marrow failure patients
Supplemental data

HOW I TREAT

How I use catheter-directed interventional therapy to treat patients with venous thromboembolism
Suresh Vedantham,Akhilesh K. Sista
View Articletitled, How I use catheter-directed interventional therapy to treat patients with venous thromboembolism

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma
Brief Report
Enrico Caserta,Junie Chea,Megan Minnix,Erasmus K. Poku,Domenico Viola,Steven Vonderfecht,Paul Yazaki,Desiree Crow,Jihane Khalife,James F. Sanchez,Joycelynne M. Palmer,Susanta Hui,Nadia Carlesso,Jonathan Keats,Young Kim,Ralf Buettner,Guido Marcucci,Steven Rosen,John Shively,David Colcher,Amrita Krishnan,Flavia Pichiorri
View Articletitled, Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma
Supplemental data

LYMPHOID NEOPLASIA

An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lydia Lee,Benjamin Draper,Neil Chaplin,Brian Philip,Melody Chin,Daria Galas-Filipowicz,Shimobi Onuoha,Simon Thomas,Vania Baldan,Reyisa Bughda,Paul Maciocia,Eva Kokalaki,Margarida P. Neves,Dominic Patel,Manuel Rodriguez-Justo,James Francis,Kwee Yong,Martin Pule
View Articletitled, An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Supplemental data
Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study
Lise M. Lindahl,Søren Besenbacher,Anne H. Rittig,Pamela Celis,Andreas Willerslev-Olsen,Lise M. R. Gjerdrum,Thorbjørn Krejsgaard,Claus Johansen,Thomas Litman,Anders Woetmann,Niels Odum,Lars Iversen
View Articletitled, Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study
Supplemental data
Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma
Rebecca Kohnken,Jing Wen,Bethany Mundy-Bosse,Kathleen McConnell,Ashleigh Keiter,Leah Grinshpun,Alex Hartlage,Max Yano,Betina McNeil,Nitin Chakravarti,Basem William,James E. Bradner,Michael A. Caligiuri,Pierluigi Porcu,Anjali Mishra
View Articletitled, Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma
Supplemental data

MYELOID NEOPLASIA

Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN
Brief Report
Shannon Elf,Nouran S. Abdelfattah,April J. Baral,Danielle Beeson,Jeanne F. Rivera,Amy Ko,Natalie Florescu,Gabriel Birrane,Edwin Chen,Ann Mullally
View Articletitled, Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN
Supplemental data

PLATELETS AND THROMBOPOIESIS

Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets
M. Edward Quach,Matthew A. Dragovich,Wenchun Chen,Anum K. Syed,Wenpeng Cao,Xin Liang,Wei Deng,Simon F. De Meyer,Guangheng Zhu,Jun Peng,Heyu Ni,Carolyn M. Bennett,Ming Hou,Jerry Ware,Hans Deckmyn,X. Frank Zhang,Renhao Li
View Articletitled, Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets
Supplemental data

THROMBOSIS AND HEMOSTASIS

Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study
Joanna Cieslik,Sandra Mrozinska,Elżbieta Broniatowska,Anetta Undas
View Articletitled, Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study
Supplemental data

TRANSPLANTATION

Evolutionary basis of HLA-DPB1 alleles affects acute GVHD in unrelated donor stem cell transplantation
Satoko Morishima,Takashi Shiina,Shingo Suzuki,Seishi Ogawa,Aiko Sato-Otsubo,Koichi Kashiwase,Fumihiro Azuma,Toshio Yabe,Masahiro Satake,Shunichi Kato,Yoshihisa Kodera,Takehiko Sasazuki,Yasuo Morishima,for the Japan Marrow Donor Program
View Articletitled, Evolutionary basis of HLA-DPB1 alleles affects acute GVHD in unrelated donor stem cell transplantation
Supplemental data

LETTERS TO BLOOD

Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Clinical Trials & Observations
Amer M. Zeidan,Maximilian Stahl,Xin Hu,Rong Wang,Scott F. Huntington,Nikolai A. Podoltsev,Steven D. Gore,Xiaomei Ma,Amy J. Davidoff
View Articletitled, Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening
Daniel Schäfer,Marianne Olsen,David Lähnemann,Martin Stanulla,Robert Slany,Kjeld Schmiegelow,Arndt Borkhardt,Ute Fischer
View Articletitled, Five percent of healthy newborns have an <em>ETV6-RUNX1</em> fusion as revealed by DNA-based GIPFEL screening
Supplemental data
Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration
Veronica Caraffini,Bianca Perfler,Johannes Lorenz Berg,Barbara Uhl,Silvia Schauer,Karl Kashofer,Nassim Ghaffari-Tabrizi-Wizsy,Herbert Strobl,Albert Wölfler,Gerald Hoefler,Heinz Sill,Armin Zebisch
View Articletitled, Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration
Supplemental data
ABO zygosity, but not secretor or Fc receptor status, is a significant risk factor for IVIG-associated hemolysis
Donald R. Branch,Åsa Hellberg,Christine W. Bruggeman,Jill R. Storry,Darinka Sakac,Megan Blacquiere,Tik Nga Tong,Emeralda Burke-Murphy,Beth Binnington,Nagina Parmar,Lorna Sampson Riden,Kezia Willie,Chantal Armali,Jiwajee Aziz,Lani Lieberman,Vincent Laroche,Jeannie Callum,Yulia Lin,Nadine Shehata,Katerina Pavenski,Wendy Lau,Barbara Hannach,Taco W. Kuijpers,Martin L. Olsson,Christine Cserti-Gazdewich,Jacob Pendergrast
View Articletitled, ABO zygosity, but not secretor or Fc receptor status, is a significant risk factor for IVIG-associated hemolysis
Supplemental data

BLOOD WORK

When it rains, it pours
Michaël Degaud,Pierre Sujobert
View Articletitled, When it rains, it pours
Jordans anomaly
Daniel Winokur,William LiPera
View Articletitled, Jordans anomaly

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Genetic landscape of inherited BMF
CME
View Articletitled, Genetic landscape of inherited BMF
All Issues

Advertisement

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma
Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study
Data mining for second malignancies after CAR-T
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement